Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study

Bettiol, Alessandra;Urban, Maria Letizia;Dagna, Lorenzo;Cottin, Vincent;Franceschini, Franco;Del Giacco, Stefano;Schiavon, Franco;Neumann, Thomas;Lopalco, Giuseppe;Novikov, Pavel;Baldini, Chiara;Lombardi, Carlo;Berti, Alvise;Alberici, Federico;Folci, Marco;Negrini, Simone;Sinico, Renato Alberto;Quartuccio, Luca;Lunardi, Claudio;Parronchi, Paola;Moosig, Frank;Espígol-Frigolé, Georgina;Schroeder, Jan;Kernder, Anna Luise;Monti, Sara;Silvagni, Ettore;Crimi, Claudia;Cinetto, Francesco;Fraticelli, Paolo;Roccatello, Dario;Vacca, Angelo;Mohammad, Aladdin J;Hellmich, Bernhard;Samson, Maxime;Bargagli, Elena;Cohen Tervaert, Jan Willem;Ribi, Camillo;Fiori, Davide;Bello, Federica;Fagni, Filippo;Moroni, Luca;Ramirez, Giuseppe Alvise;Nasser, Mouhamad;Marvisi, Chiara;Toniati, Paola;Firinu, Davide;Padoan, Roberto;Egan, Allyson;Seeliger, Benjamin;Iannone, Florenzo;Salvarani, Carlo;Jayne, David;Prisco, Domenico;Vaglio, Augusto;Emmi, Giacomo

2022-01-01

---

Abstract

Mepolizumab proved efficacious for eosinophilic granulomatosis with polyangiitis (EGPA, former Churg-Strauss) at the dosage of 300mg/4 weeks in the randomized controlled MIRRA trial. Few successful real-life experiences with the dosage approved for severe eosinophilic asthma (100mg/4 weeks) were recently reported. We retrospectively assessed the effectiveness and safety of mepolizumab 100 and 300mg/4 weeks in a large European EGPA cohort.